Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas.

Kirtane, Kedar; St John, Maie; Fuentes-Bayne, Harry; Patel, Sandip P; Mardiros, Armen; Xu, Han; Ng, Eric W; Go, William Y; Wong, Deborah J; Sunwoo, John B; Welch, John S

Kirtane, Kedar; St John, Maie; Fuentes-Bayne, Harry; Patel, Sandip P; Mardiros, Armen; Xu, Han; Ng, Eric W; Go, William Y; Wong, Deborah J; Sunwoo, John B; Welch, John S.

Afiliação

Kirtane K; Moffitt Cancer Center, Tampa, FL 33612, USA.
St John M; Otolaryngology, UCLA School of Medicine, Los Angeles, CA 90095, USA.
Fuentes-Bayne H; Mayo Clinic, Rochester, MN 55902, USA.
Patel SP; Moores Cancer Center, UCSD School of Medicine, San Diego, CA 92093, USA.
Mardiros A; A2 Biotherapeutics, Agoura Hills, CA 91301, USA.
Xu H; A2 Biotherapeutics, Agoura Hills, CA 91301, USA.
Ng EW; A2 Biotherapeutics, Agoura Hills, CA 91301, USA.
Go WY; A2 Biotherapeutics, Agoura Hills, CA 91301, USA.
Wong DJ; Otolaryngology, UCLA School of Medicine, Los Angeles, CA 90095, USA.
Sunwoo JB; Otolaryngology, Stanford University, Palo Alto, CA 94305, USA.
Welch JS; A2 Biotherapeutics, Agoura Hills, CA 91301, USA.

J Clin Med ; 11(24)2022 Dec 07.

Article em En | MEDLINE | ID: mdl-36555876

Palavras-chave

HLA; HNSCC; biomarkers; head and neck cancers; immune evasion; immuno-oncology; loss of heterozygosity (LOH); therapeutic targets

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google